Viking Therapeutics Inc (VKTX)
79.59
+1.38
(+1.76%)
USD |
NASDAQ |
May 07, 16:00
79.51
-0.08
(-0.10%)
After-Hours: 07:54
Viking Therapeutics Research and Development Expense (Annual): 63.81M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 63.81M |
| December 31, 2022 | 54.23M |
| December 31, 2021 | 44.98M |
| December 31, 2020 | 31.93M |
| December 31, 2019 | 23.56M |
| December 31, 2018 | 19.04M |
| Date | Value |
|---|---|
| December 31, 2017 | 13.74M |
| December 31, 2016 | 9.000M |
| December 31, 2015 | 6.967M |
| December 31, 2014 | 22.22M |
| December 31, 2013 | 0.0116M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
23.56M
Minimum
2019
63.81M
Maximum
2023
43.70M
Average
44.98M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Eli Lilly and Co | 9.313B |
| Pfizer Inc | 10.68B |
| Madrigal Pharmaceuticals Inc | 272.35M |
| Akero Therapeutics Inc | 141.80M |
| Terns Pharmaceuticals Inc | 63.50M |